Introduction
Interleukin-12 (IL-12) is a heterodimeric cytokine produced primarily by antigen-presenting cells. 1,2 IL-12 has a variety of immunoregulatory effects on both T cells and natural killer (NK) cells, including the induction of interferon-␥ (IFN-␥) production and enhancement of cytolytic activity. IL-12 also enhances the proliferation of activated T cells and promotes T H 1-type immune responses. 3 IL-12 mediates its biological effects by signaling through specific cell surface receptors, which activate the Jak-signal transducer and activator of transcription (STAT) pathways. The functional IL-12 receptor is a heterodimeric receptor consisting of 2 subunits, termed IL-12R␤1 and IL-12R␤2. 4, 5 The intracellular signaling pathway of IL-12 involves 2 members of the Janus kinase family, Jak2 and Tyk2, and several members of the STAT transcription activator family, including STAT1, STAT4, and STAT5. [6] [7] [8] Among the STATs that are involved in IL-12 signaling, STAT4 plays a critical role. STAT4 knockout mice exhibit abrogation of all major IL-12-induced functions in both T cells and NK cells, including loss of IFN-␥ production and impaired T H 1 responses. 9, 10 Previous studies have demonstrated that a variety of other cytokines modulate the response of cells to IL-12. These effects occur through modulation of different components of the IL-12 signaling pathway. For example, the expression of IL-12R␤2 appears to be highly regulated in different cell types. IL-2, IL-12, and IFN-␥ enhance the expression of IL-12R␤2 in NK cells and T cells, and IL-4 inhibits the expression of this receptor component in T cells. [11] [12] [13] [14] Recent studies have shown that different cytokines can also modulate STAT expression. In NK cells, the expression of STAT1 is enhanced by IL-2 and IL-12 and the expression of STAT4 is enhanced by IL-2. 11 The ability of IL-12 to enhance the cytotoxicity of NK cells and cytotoxic T lymphocytes (CTLs) probably plays a role in the therapeutic potential of IL-12 in patients with cancer. Preclinical studies in animal models demonstrated that administration of IL-12 resulted in regression of established tumors and activation of antitumor immunity. [15] [16] [17] [18] It was also demonstrated that treatment with a single dose of IL-12 augmented the cytolytic activity and proliferation of lymphocytes in cancer patients. 19 However, significant antitumor effects were not observed in patients treated with IL-12. 20, 21 The production of IFN-␥ induced by administration of IL-12 in these patients was dramatically decreased following continued treatment with IL-12, indicating a loss of responsiveness to IL-12 during treatment. 20 This loss of responsiveness may contribute to the ineffectiveness of IL-12 in clinical trials. To understand the mechanism underlying the loss of responsiveness, we investigated the effect of IL-12 treatment in vitro on IL-12 signaling in human T cells. We found that IL-12 treatment significantly affected the expression of several components of its own signaling pathway. The most functionally significant effect appeared to be reduced cellular levels of STAT4 protein. These findings provide insights into the mechanism for regulating IL-12 function in vivo and may explain the loss of responsiveness observed in IL-12 clinical trials.
Materials and methods

Cytokines, antibodies, and reagents
Recombinant human IL-2 was provided by Amgen (Thousand Oaks, CA). Human recombinant IL-12 was provided by the Genetics Institute (Cambridge, MA). Human IFN-␣ was obtained from Schering-Plough (Madison, NJ). Purified unconjugated mouse anti-CD3 (immunoglobulin G2a [IgG2a]) and isotype control MsIgG1 were provided by Beckman Coulter (Hialeah, FL). Phycoerythrin (PE)-conjugated goat antimouse IgG1 was purchased from Southern Biotechnology (Birmingham, AL). The generation of mouse monoclonal anti-IL-12R␤1 and ␤2 subunits, ␤44 and 5A7, was described previously. 11, 13 Antibodies specific for STAT1, STAT5, STAT4, Tyk2, and Jak2 and phosphotyrosine antibody PY99 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Proteasome inhibitor MG-132 was purchased from Calbiochem (San Diego, CA). The anti-phosphotyrosine-STAT1, which also cross-reacts with phosphotyrosine-STAT5, was described previously. 22 
Enrichment and culture of human T cells
Enriched white blood cells were obtained from healthy donors undergoing platelet pheresis at the Dana-Farber Cancer Institute Blood Donor Center, Boston, MA. Peripheral blood mononuclear cells were isolated by FicollHypaque (Pharmacia LKB, Piscataway, NJ) gradient centrifugation and nylon wool column depletion. The remaining cell population contains more than 90% T cells. Cells were then cultured at 2 ϫ 10 6 cells/mL with RPMI 1640 medium containing 15% fetal calf serum for 3 days in a 175-cm 2 flask coated with 20 g anti-CD3 to induce the expression of IL-12R␤2. Activated T cells were transferred into a 25-cm 2 flask coated with 2 g anti-CD3 and cultured at 2 ϫ 10 6 cells/mL with or without cytokines for various times. All cytokines were used at 100 U/mL, if not otherwise specified.
Immunofluorescence analysis of IL-12R expression
CD3-activated T cells were cultured with or without indicated cytokines for 3 days. Cells were labeled with IgG1 isotype control, anti-IL-12R␤1 antibody (12R␤44) or anti-IL-12R␤2 antibody (5A7). Cells were then labeled with secondary antibody PE-conjugated goat antimouse IgG1. The expression of IL-12R␤1 and ␤2 was analyzed on a Coulter EPICS XL flow cytometer.
Western blotting and Northern blot analysis of STAT4 messenger RNA
Whole-cell extracts were prepared and Western blot was performed as described previously. 23 Total RNA was prepared from activated T cells that were cultured with or without cytokines for 24 hours. We used 20 g total RNA in Northern blot analysis. The probe used for Northern blotting was generated by reverse transcriptase-polymerase chain reaction (RT-PCR) with total RNA from activated T cells and 2 STAT4-specific primers designed according to the STAT4 complementary DNA (cDNA) sequence in GenBank (Accession L78440). Reverse transcription and PCR were performed as described previously. 24 
Immunoprecipitation of STAT4 protein
Whole-cell extracts from 20 ϫ 10 6 untreated or treated cells were prepared, and the STAT4 protein was immunoprecipitated with 10 g STAT4 antibody as described previously. 23 Nuclear extracts and electrophoretic mobility shift assay Activated T cells were cultured with or without cytokines in anti-CD3-coated flasks for 24 hours. Cells were then treated with IL-12 for 20 minutes. Nuclear extracts were prepared and the electrophoretic mobility shift assay (EMSA) was performed as previously described. 23 The STATbinding oligonucleotides used, 5Ј-GAGCCTGATTTCCCCGAAATGAT-GAGC-3Ј and its complement, are derived from the IFN-␥-responsive factor 1 gene promoter. 25 
IFN-␥ enzyme-linked immunosorbent assay
CD3-activated T cells were cultured with or without cytokines in anti-CD3-coated flasks for 2 days. Cells were then washed and plated at 50 000 cells per well in duplicate into 96-well U-bottom plates and cultured with or without IL-12 for 2 days. The supernatants were collected, and the concentration of IFN-␥ in all supernatants was determined by IFN-␥ enzyme-linked immunosorbent assay (ELISA) (Endogen, Boston, MA).
Proliferation assay
CD3-activated T cells were cultured with or without cytokines in anti-CD3-coated flasks for 2 days. Cells were then washed and plated at 30 11 The effect of IL-12 on the expression of the 2 kinases involved in IL-12 signaling, Jak2 and Tyk2, was also examined, and neither kinase was decreased at the protein level after IL-12 treatment (data not shown). This result indicated that among the kinases and STATs that are involved in IL-12 signaling, the expression of STAT4 protein was specifically down-regulated by IL-12. Because STAT4 is the major STAT involved in IL-12 signaling, the down-regulation of STAT4 expression by IL-12 may have functional consequences on the subsequent T-cell responsiveness to IL-12. Figure 4A ). 11 Moreover, T cells that were pretreated with IL-12, either alone or in combination with IL-2, also showed significantly reduced proliferative response 
Inhibition of proteasome-pathway degradation blocks IL-12-induced down-regulation of STAT4 protein
The proteasome pathway has been shown to be involved in the turnover of tyrosine phospho-STATs activated in several signaling pathways. [26] [27] [28] To examine whether the proteasome pathway is also involved in the down-regulation of STAT4, we examined the effect of a specific inhibitor of this pathway, MG-132, on the down- Figure 6A, bottom panel) . These observations suggest that degradation through the proteasome pathway specifically targets phospho-STAT4. The delayed activation of this degradation process suggests that phosphorylation of STAT4 alone may not be sufficient for the degradation of STAT4. Other IL-12-induced factors may also be involved in this process.
Down-regulation of STAT4 through the proteasome pathway is specific for IL-12 signaling
IFN-␣ is also known to induce phosphorylation of STAT4. 29 To investigate whether the down-regulation of STAT4 is specific for IL-12, we examined the effect of MG-132 on IFN-␣-induced activation of STAT4. As shown in Figure 7 , activated T cells were stimulated for 6 hours with IFN-␣, and results were compared with similar treatment with IL-12. In contrast to IL-12-treated T cells, there was no visible phospho-STAT4 band in the IFN-␣-treated T cells (Figure 7, lanes 7 and 8) , and there is a low level of phospho-STAT4 accumulation after MG-132 treatment (Figure 7 , lane 9). The unphosphorylated STAT4 continues to represent the predominant STAT4 band in cells treated with MG-132 ( Figure 7 , lane 9). To understand the mechanism that leads to the different effects of MG-132 on phospho-STAT4 induced by these 2 cytokines, we compared the kinetics of STAT4 activation. As shown in Figure 8 , IL-12-treated T cells exhibited persistent activation of STAT4 as indicated by the appearance of a shifted STAT4 band throughout the time we tested. This was associated with a marked decrease of total STAT4 protein by 24 hours (Figure 8, top panel) . However, IFN-␣ induced only a transient phosphorylation of STAT4, as indicated by the disappearance of the shifted STAT4 band by 6 hours (Figure 8, panel 3) . In contrast to IL-12-treated T cells, the level of STAT4 protein in IFN-␣-treated T cells was maintained at a similar level throughout the time we observed. These observations suggest that although both IL-12 and IFN-␣ induce activation of STAT4, the degradation of phospho-STAT4 was specific for the IL-12 signaling pathway. This may be attributed to the persistent activation of STAT4 induced by IL-12 rather than the transient activation of STAT4 induced by IFN-␣.
Discussion
In previous studies, it has been demonstrated that expression of the IL-12 receptor can be modulated by other cytokines, such as IL-2 and IL-4, and that this provides an important mechanism for the regulation of IL-12 responsiveness. IL-12 also modulates further responsiveness to IL-12, but the mechanism whereby IL-12 autoregulation occurs has not been defined. In the present study, we examined various components of the IL-12 signaling pathway in activated human T cells and confirmed that once these cells have been activated by IL-12, they become resistant to further IL-12 stimulation. This specific down-regulation of IL-12 signaling appears to be mediated primarily through reduced levels of STAT4 protein, a critical component of the IL-12 signaling pathway. Decreased levels of STAT4 following IL-12 activation do not appear to result from decreased STAT4 gene transcription but from increased degradation of STAT4 protein. Initial experiments suggest that this increased degradation specifically targets the tyrosinephosphorylated STAT4 protein that results from IL-12-induced activation. Other STAT proteins and STAT4 activation following IFN-␣ signaling are not regulated in this fashion, and this therefore appears to represent a unique regulatory mechanism whereby IL-12 down-regulates the responsiveness of activated T cells to further IL-12 stimulation.
Cytokine signaling through the Jak-STAT pathways involves the phosphorylation of STAT proteins by Jak kinases, the translocation of phospho-STATs to the nucleus, the dephosphorylation of STATs by tyrosine phosphatase in the nucleus, and the return of the dephosphorylated STAT protein to the cytoplasm. 27 Several mechanisms have previously been shown to regulate this signaling pathway. One mechanism is inhibition of STAT phosphorylation by members of the suppressor of cytokine signaling (SOCS) family. SOCS proteins are induced following cytokine stimulation, bind to Jak kinases, and inhibit activated Jak kinases from further phosphorylation of STAT proteins. 30, 31 This mechanism has been shown to down-regulate IFN-␥, IL-3, IL-6, and IFN-␣ signaling. 32, 33 As a result of inhibition by SOCS proteins, STAT signaling becomes a transient response, and levels of phosphorylated STAT proteins decrease within hours of activation. However, the SOCS feedback mechanism does not result in reduced levels of STAT proteins. Another mechanism known to down-regulate STAT signaling involves tyrosine phosphatases, such as SHP-1 and SHP-2. These tyrosine phosphatases have been shown to down-regulate the activity of STAT1, STAT3, or STAT5 following activation by IFN-␥, leukemia inhibitory factor, or IL-2 either by dephosphorylating STAT proteins directly or through dephosphorylation of Jak kinases. [34] [35] [36] Like the SOCS feedback mechanism, the downregulation through tyrosine phosphatases also results in transient activation of STAT proteins and does not lead to reduced levels of STAT proteins. The transient activation of STAT4 by IFN-␣ may reflect the involvement of SOCS proteins or other mechanisms in down-regulating the IFN-␣ signaling. However, the persistence of phospho-STAT4 and loss of STAT4 protein in IL-12-treated T cells suggest that it is unlikely that either of these mechanisms contribute to the down-regulation of IL-12 signaling following IL-12 activation.
Several studies have demonstrated that the proteasome pathway can be involved in the turnover of phosphorylated STAT proteins. In previous studies, addition of the proteasome-specific inhibitor MG-132 was shown to prolong the tyrosine phosphorylation of STAT1, STAT4, STAT5, and STAT6 induced by IFN-␥, IL-2, IL-3, IL-4, or IL-12. 11, [26] [27] [28] This suggests that the proteasome pathway may also contribute to the transient activation of STAT proteins following cytokine signaling. However, no down-regulation of total STAT proteins were observed in these systems. In particular, Wang et al 11 demonstrated that MG-132 prolonged the tyrosine phosphorylation of STAT4 in the Kit225 cell line, but the activation of STAT4 by IL-12 in their system appeared to be transient and no loss of total STAT4 was noted. The persistent phosphorylation of STAT4 and the loss of STAT4 protein after IL-12 stimulation appear to represent a unique example of autoregulation of cytokine signaling. MG-132 inhibition of the down-regulation of STAT4 by IL-12 in our experiments suggests that the proteasome pathway may play an important role in the modulation of cytokine signaling. Following IFN-␣ signaling, the transient activation of STAT4 suggests that other negative feedback mechanisms are activated, and the proteasome pathway does not appear to play a major role in the down-regulation of this signaling pathway. However, following IL-12 stimulation, STAT4 is persistently activated, and the proteasome pathway appears to play a major role in the down-regulation of this signaling pathway. These observations suggest that degradation of phospho-STATs through the proteasome pathway, which leads to the depletion of cellular STAT protein, represents an important alternative mechanism for down-regulating a signaling pathway where other negative feedback mechanisms are not activated.
The depletion of cellular STAT4 in activated T cells markedly affects the function of these cells and specifically reduces their ability to secrete IFN-␥ and proliferate in response to further IL-12 stimulation. These deficiencies are similar to those observed in STAT4 knockout mice, which have markedly impaired ability to develop T H 1 responses. 9, 10 Although IL-12 is known to be a primary stimulating cytokine for initiation of T H 1 responses, these observations suggest that persistent stimulation with IL-12 will also inhibit the T H 1 response in vivo. Thus, IL-12 appears to be able to both initiate a T H 1 response and subsequently limit further T H 1 responses if the production of IL-12 persists for prolonged periods. These opposing functional effects appear to be mediated through initial activation of STAT4 followed by the depletion of STAT4 protein after prolonged IL-12 activation.
Although IL-12 has been shown to activate STAT1 in addition to STAT4, our results demonstrated that neither STAT1 nor phospho-STAT1 was depleted after IL-12 activation. This finding suggests that the degradation process activated by IL-12 is specific for STAT4 and does not affect other STAT proteins activated in the same pathway. In addition, STAT4 was not depleted after IFN-␣ stimulation. These results suggest that STAT4 degradation may include an active recruiting process that involves one or more factors capable of recognizing and targeting phosphorylated STAT4 to the degradation pathway. The delayed onset of the degradation process and the specificity for STAT4 suggest that the activation of these factors may also require the persistent activation of STAT4 itself. The identity of these factors and the mechanism by which they recruit phospho-STAT4 and down-regulate the IL-12 signaling pathway require further investigation.
The negative regulation of IL-12 signaling through downregulation of STAT4 expression may contribute to the ineffectiveness of IL-12 in clinical trials in patients with cancer. In these studies, single doses of IL-12 augment the cytolytic activity, secretion of INF-␥, and proliferation of lymphocytes in vivo. 19 However, these immunologic effects were not sustained with continued treatment. Unlike many other cytokines, IL-12 is a relatively large heterodimeric molecule that is not rapidly degraded or excreted. 21 The relatively long half-life of infused recombinant IL-12 leads to the persistence of physiologic levels of active cytokine for prolonged periods after each administration, and this further prolongs the cellular activation mediated by exogenous IL-12. Our studies suggest that the prolonged half-life of IL-12 may therefore also contribute to the selective depletion of STAT4 following IL-12 treatment and loss of responsiveness in vivo. The effectiveness of IL-12 as a therapeutic agent for cancer treatment may depend on the design of alternative treatment regimens or the development of IL-12 agonists with shorter half-lives. Our results suggest that the immunologic effects of IL-12 on T cells would be enhanced by intermittent administration of relatively low doses of IL-12. This schedule would allow cellular levels of STAT4 to recover after each treatment. Intermittent administration of IL-12 alternating with doses of IL-2 would also be expected to enhance recovery of STAT4 and enhance IL-12 responsiveness. 11 In contrast, continuous exposure to IL-12, either with or without IL-2, would be expected to suppress cellular STAT4 for prolonged periods and reduce responsiveness to IL-12. These types of schedules can be evaluated in future clinical trials and may provide a mechanism for effectively enhancing the cytolytic activity of NK cells and CTLs in vivo. 
